PRESS RELEASE published on 04/29/2025 at 22:05, 1 year 6 months ago Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax completes enrollment for Phase 3 ABTECT Trials in patients with active ulcerative colitis. Top-line results expected in Q3 2025, NDA submission planned for H2 2026 Abivax Ulcerative Colitis Phase 3 ABTECT Trials NDA Submission
BRIEF published on 04/22/2025 at 22:10, 1 year 6 months ago Abivax: Terms of the Annual General Meeting and outlook for 2025 Biotechnology Abivax Clinical Trials Investment General Meeting 2025
BRIEF published on 04/22/2025 at 22:05, 1 year 6 months ago Abivax welcomes Dr. Dominik Höchli to its Board of Directors Board Of Directors Abivax Phase 3 Immunology Dominik Höchli
PRESS RELEASE published on 04/22/2025 at 22:05, 1 year 6 months ago Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax announces details of Annual General Meeting on June 6, 2025, in Paris as it progresses towards key 2025 milestones, including Phase 3 ABTECT trials Annual General Meeting Abivax Clinical-stage Biotechnology Phase 3 ABTECT Trials 2025 Milestones
PRESS RELEASE published on 04/22/2025 at 22:00, 1 year 6 months ago Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax appoints Dominik Höchli, MD to Board of Directors, bringing extensive immunology expertise ahead of key Phase 3 data readout in ulcerative colitis in Q3 2025 Board Of Directors Abivax Ulcerative Colitis Dominik Höchli Phase 3 Data Readout
BRIEF published on 04/18/2025 at 18:05, 1 year 6 months ago ABIVAX: Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Actions Abivax
BRIEF published on 04/18/2025 at 18:05, 1 year 6 months ago ABIVAX: Details of Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF published on 03/27/2025 at 18:05, 1 year 7 months ago ABIVAX: Update of share capital and voting rights Share Capital Voting Rights Biotechnology AMF Abivax
BRIEF published on 03/26/2025 at 22:10, 1 year 7 months ago Abivax publishes its 2024 financial reports Biotechnology AMF Abivax Financial Reports DRY
PRESS RELEASE published on 03/26/2025 at 22:05, 1 year 7 months ago Abivax publishes financial reports with the French and U.S. securities regulatory agencies Abivax publishes financial reports with French and U.S. securities regulatory agencies. The company filed its Universal Registration Document and Annual Report for 2024 Abivax Financial Reports Regulatory Agencies U.S. Securities French
Published on 10/30/2026 at 23:35, 2 days 6 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 6 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 11 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 14 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 06:00, 25 minutes ago Wujiang Marks 90 Years Since Fei Xiaotong's Jiangcun Field Study
Published on 11/01/2026 at 10:35, 19 hours 50 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day 1 hour ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 13 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 7 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 7 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 12 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 18 hours ago Capital increase through exercise of subscription rights
